Cambridge Cognition Holdings Plc (LSE:COG), the brain health technology company, has reported a 16% rise in first-half revenue and a narrower loss, as early pilots in healthcare and consumer wellness began contributing alongside its core clinical trials business. The interim results, published on 16 September 2026, also showed the company had become debt-free after a £2.6m fundraise in July, although the directors continue to flag a material uncertainty over going concern.

What the company does

Cambridge Cognition develops digital tools for assessing cognitive function. Its best-known product, CANTAB, is a suite of computerised tests used in academic studies and by pharmaceutical companies running clinical trials in areas such as neurology and psychiatry. The company also provides electronic clinical outcome assessment technology, and is adapting its platform for healthcare providers and consumer health applications. Rob Baker is chief executive.

Latest developments

For the six months to 30 June 2026, revenue rose to £5.0m from £4.3m, including £0.1m from new healthcare and consumer wellness pilots. New sales orders fell 13% to £6.0m, which the company attributed to a £1.0m contract signed three working days after the period end. The order book stood at £16.1m.

Several commercial milestones were reported. A major European private healthcare group moved from a completed pilot to long-term use of the company's tools and is considering wider geographic expansion. A brain health study with smart ring maker ŌURA went live in June and reached its target of 45,000 participants. In India, partner Ivory is commercialising CANTAB Pathway across healthcare and consumer health. The number of clinical studies using the company's technology rose 18% to 71, and academic projects rose to 260.

Baker described a strategy of building technology once and deploying it across clinical, healthcare and consumer markets, and said investment programmes were on time and on budget.

Financial and dividend picture

The operating loss narrowed to £0.6m from £0.8m, and the loss for the period fell to £0.7m from £1.0m. The adjusted EBITDA loss was £0.3m, while EBITDA before development spending rose 21% to £0.7m. The company generated an operating cash inflow of £0.3m, compared with an outflow a year earlier.

Cash was £0.6m at 30 June. In July the company completed a £2.6m gross fundraise and repaid its remaining borrowings. It expects full-year 2026 revenue of at least £10.0m based on contracted orders, with about £0.7m of contracted revenue moving into 2027 because of client timing. The order book already covers £6.6m of 2027 revenue. The company does not pay a dividend.

Sector and index context

Cambridge Cognition is a small constituent of the FTSE AIM All Share Index within the healthcare technology space. Its clinical revenue depends on pharmaceutical development budgets, particularly in central nervous system trials, which have been affected by biotech funding conditions. Consumer and healthcare brain health monitoring is an emerging market with growing interest from wearable device makers.

Key risks

The directors' going concern statement notes a material uncertainty that may cast significant doubt on the company's ability to continue as a going concern, even though accounts are prepared on that basis. Order intake can be lumpy, and delays in client trials can push revenue into later periods. The new healthcare and consumer markets are unproven at scale, and the pace at which pilots turn into paying contracts remains uncertain.

What to watch next

Investors will look for delivery of at least £10.0m of revenue in 2026, order intake in the second half, conversion of pilots into recurring contracts and any further partnerships in consumer health. Progress with the European healthcare group and the commercial rollout in India will also show whether Cambridge Cognition (LSE:COG) can build a meaningful second revenue stream beyond clinical trials.